lukSF-PV in Staphylococcus aureus keratitis isolates and association with clinical outcome

Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3410-6. doi: 10.1167/iovs.12-11276.

Abstract

Purpose: To determine the prevalence, genetic diversity, and clinical relevance of the lukSF-PV gene, encoding the bacterial toxin Panton-Valentine leukocidin, in Staphylococcus aureus isolates from cases of bacterial keratitis in the United Kingdom.

Methods: Multiplex PCRs investigating carriage of lukSF-PV and mecA were performed on S. aureus isolates from patients. The lukSF-PV operon was sequenced to investigate its diversity, and multilocus sequence typing to test for a clonal relationship between lukSF-PV isolates. Antimicrobial minimum inhibitory concentrations (MICs) and clinical outcome data were compared for isolates characterized as lukSF-PV+ve, mecA+ve, and lukSF-PV/mecA-ve.

Results: Of 95 isolates, 9 (9.5%) were lukSF-PV+ve, 9 (9.5%) mecA+ve, and 1 was positive for both. Five single nucleotide polymorphisms were found in lukSF-PV genes of seven strains. There was no significant difference between the MICs of lukSF-PV/mecA-ve and lukSF-PV+ve isolates to the antimicrobials tested, except for tigecycline (P < 0.05). The mecA+ve isolates had significantly higher mean MICs to meropenem and fluoroquinolones (P < 0.05). There were nonsignificant trends for healing and treatment times, ulcer and scar size, and overall clinical score to be greater in the lukSF-PV+ve group (P < 0.05). The proportion of patients, however, who required surgery was significantly greater among patients with lukSF-PV+ve isolates with an odds ratio of 7.8 (95% CI 1-42, P = 0.018) for patients requiring surgery.

Conclusions: lukSF-PV+ve isolates were associated with a trend to worse clinical outcome and more surgical interventions, with an effect unrelated to MICs. This suggests that lukSF-PV may be an important virulence factor in S. aureus-associated keratitis.

Keywords: Panton-Valentine leukocidin; Staphylococcus aureus keratitis; keratitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics*
  • Bacterial Proteins / metabolism
  • Bacterial Toxins / genetics*
  • Bacterial Toxins / metabolism
  • Corneal Ulcer / drug therapy
  • Corneal Ulcer / microbiology*
  • Exotoxins / genetics*
  • Exotoxins / metabolism
  • Female
  • Fluoroquinolones / therapeutic use
  • Humans
  • Leukocidins / genetics*
  • Leukocidins / metabolism
  • Male
  • Penicillin-Binding Proteins
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / microbiology*
  • Staphylococcus aureus / genetics*
  • Staphylococcus aureus / isolation & purification
  • Staphylococcus aureus / pathogenicity
  • United Kingdom
  • Virulence

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Bacterial Toxins
  • Exotoxins
  • Fluoroquinolones
  • Leukocidins
  • Panton-Valentine leukocidin
  • Penicillin-Binding Proteins
  • leukocidin S-component protein, Staphylococcus
  • mecA protein, Staphylococcus aureus
  • LukF protein, Staphylococcus aureus